Abstract: Objective To explore the effect of combining TACE with PMCT in patients with advanced liver cancer.Methods From March 2018 to April 2020, 60 patients with advanced liver cancer admitted to Yixing People′s Hospital were randomly divided into two groups, with 30 patients in each groups. The patients in the short interval group received simultaneous treatment with TACE and PMCT. The patients in the long interval group received PMCT one month after TACE. After 3 months of treatment, the clinical efficacy, AFP, abnormal prothrombin levels and 2-year survival rate were compared. Results The objective remission rates of short interval group and long interval group after treatment were 43.33% and 36.67% respectively, and there was no significant difference between the two groups (P>0.05). After treatment, the levels of serum AFP and abnormal prothrombin in the short interval group were (107.43±15.32) ng/mL and (2831.26±118.50) mAU/mL, respectively. In the long interval group, the levels of serum AFP and abnormal prothrombin were (135.02±12.51) ng/mL and (3135.65±107.28) mAU/mL, respectively. Both groups showed lower levels of serum AFP and abnormal prothrombin after treatment compared to before treatment, with the short interval group showing a greater reduction (P<0.05).). The 2-year overall survival rates of the long interval group and the short interval group were 23.08% and 46.43%, respectively. The survival curves of the two groups were statistically different (P<0.05). Conclusion PMCT at the same time of TACE treatment is more helpful in inhibiting the expression of tumor factors in patients with advanced liver cancer, prolonging the survival period, and ensuring good safety.

Key words: Advanced liver cancer, TACE, PMCT, Survival rate